Zobrazeno 1 - 10
of 375
pro vyhledávání: '"Paul S Mischel"'
Autor:
Miin S Lin, Se-Young Jo, Jens Luebeck, Howard Y Chang, Sihan Wu, Paul S Mischel, Vineet Bafna
Publikováno v:
eLife, Vol 12 (2024)
Extrachromosomal DNA is a common cause of oncogene amplification in cancer. The non-chromosomal inheritance of ecDNA enables tumors to rapidly evolve, contributing to treatment resistance and poor outcome for patients. The transcriptional context in
Externí odkaz:
https://doaj.org/article/046c3f6729814f22a71b2d46f9439236
Autor:
Nicholas A Graham, Martik Tahmasian, Bitika Kohli, Evangelia Komisopoulou, Maggie Zhu, Igor Vivanco, Michael A Teitell, Hong Wu, Antoni Ribas, Roger S Lo, Ingo K Mellinghoff, Paul S Mischel, Thomas G Graeber
Publikováno v:
Molecular Systems Biology, Vol 8, Iss 1, Pp 1-16 (2012)
Abstract The altered metabolism of cancer can render cells dependent on the availability of metabolic substrates for viability. Investigating the signaling mechanisms underlying cell death in cells dependent upon glucose for survival, we demonstrate
Externí odkaz:
https://doaj.org/article/ee846cbd9aaa4f49a9bd39d8351540f9
Autor:
Renee D Read, Tim R Fenton, German G Gomez, Jill Wykosky, Scott R Vandenberg, Ivan Babic, Akio Iwanami, Huijun Yang, Webster K Cavenee, Paul S Mischel, Frank B Furnari, John B Thomas
Publikováno v:
PLoS Genetics, Vol 9, Iss 2, p e1003253 (2013)
Glioblastoma, the most common primary malignant brain tumor, is incurable with current therapies. Genetic and molecular analyses demonstrate that glioblastomas frequently display mutations that activate receptor tyrosine kinase (RTK) and Pi-3 kinase
Externí odkaz:
https://doaj.org/article/f66c2079edd64ea7b75880e80cd51118
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e61505 (2013)
Since hub nodes have been found to play important roles in many networks, highly connected hub genes are expected to play an important role in biology as well. However, the empirical evidence remains ambiguous. An open question is whether (or when) h
Externí odkaz:
https://doaj.org/article/11dca275fb6f4220844cfa24aae66a02
Autor:
Fei Ye, Yibei Zhang, Yue Liu, Kazunari Yamada, Jonathan L Tso, Jimmy C Menjivar, Jane Y Tian, William H Yong, Dörthe Schaue, Paul S Mischel, Timothy F Cloughesy, Stanley F Nelson, Linda M Liau, William McBride, Cho-Lea Tso
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e80397 (2013)
Glioblastoma stem cells (GSC) are a significant cell model for explaining brain tumor recurrence. However, mechanisms underlying their radiochemoresistance remain obscure. Here we show that most clonogenic cells in GSC cultures are sensitive to radia
Externí odkaz:
https://doaj.org/article/a036ccf297544e5ebd3010afa96febf1
Autor:
Linh M Tran, Chun-Ju Chang, Seema Plaisier, Shumin Wu, Julie Dang, Paul S Mischel, James C Liao, Thomas G Graeber, Hong Wu
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e31053 (2012)
PTEN-controlled PI3K-AKT-mTOR pathway represents one of the most deregulated signaling pathways in human cancers. With many small molecule inhibitors that target PI3K-AKT-mTOR pathway being exploited clinically, sensitive and reliable ways of stratif
Externí odkaz:
https://doaj.org/article/b1f9f000f2434456aa5b6fcab54d8920
Autor:
Jun Muto, Takao Imai, Daisuke Ogawa, Yoshinori Nishimoto, Yohei Okada, Yo Mabuchi, Takeshi Kawase, Akio Iwanami, Paul S Mischel, Hideyuki Saya, Kazunari Yoshida, Yumi Matsuzaki, Hideyuki Okano
Publikováno v:
PLoS ONE, Vol 7, Iss 3, p e33431 (2012)
Musashi1 (MSI1) is an RNA-binding protein that plays critical roles in nervous-system development and stem-cell self-renewal. Here, we examined its role in the progression of glioma. Short hairpin RNA (shRNA)-based MSI1-knock down (KD) in glioblastom
Externí odkaz:
https://doaj.org/article/7204904c03124dbeaa66a3ade5827fec
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
Autor:
Mohammad Atefi, Erika von Euw, Narsis Attar, Charles Ng, Connie Chu, Deliang Guo, Ramin Nazarian, Bartosz Chmielowski, John A Glaspy, Begonya Comin-Anduix, Paul S Mischel, Roger S Lo, Antoni Ribas
Publikováno v:
PLoS ONE, Vol 6, Iss 12, p e28973 (2011)
The sustained clinical activity of the BRAF inhibitor vemurafenib (PLX4032/RG7204) in patients with BRAF(V600) mutant melanoma is limited primarily by the development of acquired resistance leading to tumor progression. Clinical trials are in progres
Externí odkaz:
https://doaj.org/article/f5dd53cf6f154f0b8e16f8e436c784c9
Autor:
Mayumi Jijiwa, Habibe Demir, Snehalata Gupta, Crystal Leung, Kaushal Joshi, Nicholas Orozco, Tiffany Huang, Vedat O Yildiz, Ichiyo Shibahara, Jason A de Jesus, William H Yong, Paul S Mischel, Soledad Fernandez, Harley I Kornblum, Ichiro Nakano
Publikováno v:
PLoS ONE, Vol 6, Iss 9, p e24217 (2011)
Identification of stem cell-like brain tumor cells (brain tumor stem-like cells; BTSC) has gained substantial attention by scientists and physicians. However, the mechanism of tumor initiation and proliferation is still poorly understood. CD44 is a c
Externí odkaz:
https://doaj.org/article/021a9cd0b3f2486ebcc191e4ebd9cf03
Autor:
Tim F Cloughesy, Koji Yoshimoto, Phioanh Nghiemphu, Kevin Brown, Julie Dang, Shaojun Zhu, Teli Hsueh, Yinan Chen, Wei Wang, David Youngkin, Linda Liau, Neil Martin, Don Becker, Marvin Bergsneider, Albert Lai, Richard Green, Tom Oglesby, Michael Koleto, Jeff Trent, Steve Horvath, Paul S Mischel, Ingo K Mellinghoff, Charles L Sawyers
Publikováno v:
PLoS Medicine, Vol 5, Iss 1, p e8 (2008)
There is much discussion in the cancer drug development community about how to incorporate molecular tools into early-stage clinical trials to assess target modulation, measure anti-tumor activity, and enrich the clinical trial population for patient
Externí odkaz:
https://doaj.org/article/6c668f88ea25476fae7fe61ad50c3162